0001127602-23-023040.txt : 20230821
0001127602-23-023040.hdr.sgml : 20230821
20230821193630
ACCESSION NUMBER: 0001127602-23-023040
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230814
FILED AS OF DATE: 20230821
DATE AS OF CHANGE: 20230821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Busch Matthew C.
CENTRAL INDEX KEY: 0001987926
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 231190664
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
3
1
form3.xml
PRIMARY DOCUMENT
X0206
3
2023-08-14
0
0000318154
AMGEN INC
AMGN
0001987926
Busch Matthew C.
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320
1
VP, Finance & CAO
Common Stock
4596
D
Nqso (Right to Buy)
177.46
2020-04-27
2028-04-27
Common Stock
1257
D
Nqso (Right to Buy)
177.31
2021-05-03
2029-05-03
Common Stock
1476
D
Nqso (Right to Buy)
236.36
2022-05-05
2030-05-05
Common Stock
1558
D
Nqso (Right to Buy)
239.64
2023-04-30
2031-04-30
Common Stock
1086
D
Nqso (Right to Buy)
230.92
2024-05-02
2032-05-02
Common Stock
1753
D
Nqso (Right to Buy)
235.97
2025-05-02
2033-05-02
Common Stock
2508
D
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 1,496 RSUs which will vest in installments of 493 on 11/5/2023, 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 126 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
1,257 of these non-qualified stock options have vested and are exercisable.
1,476 of these non-qualified stock options have vested and are exercisable.
1,028 of these non-qualified stock options have vested and 530 will vest and become exercisable on 5/5/2024.
358 of these non-qualified stock options have vested and the remaining options will vest and become exercisable in installments of 358 on 4/30/2024 and 370 on 4/30/2025.
These non-qualified stock options will vest and become exercisable in two installments of 578 on 5/2/2024 and 5/2/2025 and one installment of 597 on 5/2/2026.
These non-qualified stock options will vest and become exercisable in installments of 827 on 5/2/2025, 828 on 5/2/2026 and 853 on 5/2/2027.
/s/ Matthew C. Busch
2023-08-21
EX-24
2
doc1.txt
POWER OF ATTORNEY (PUBLIC): POA
Exhibit 24
Power of Attorney
Know all men by these presents, that the undersigned hereby
constitutes and appoints each of Dennis Yai and Andrea A. Robinson,
signing singly, the undersigned's true and lawful attorney-in-fact to
execute for and on behalf of the undersigned Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended, and the rules thereunder, as may be required as a result
of the undersigneds position as an officer and/or director of Amgen Inc.
(the "Company").
The undersigned hereby grants to each such attorney-in-fact
full power and authority to execute such Forms 3, 4 and 5 as fully to all
intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the Securities Exchange Act
of 1934, as amended.
This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms 3, 4
and 5 with respect to the undersigneds holdings of and transactions
in securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of this 21st day of July, 2023.
/s/ Matthew C. Busch
Name: Matthew C. Busch